Charles River Laboratories | CRL - Operating Profit

Stock Price
150.85
Daily Change
-8.27 -5.20%
Monthly
-14.75%
Yearly
7.01%
Q2 Forecast
147.82

Charles River Laboratories reported $119.9M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Agilent USD 353M 90M Dec/2025
Align Technology USD 178.05M 46.66M Mar/2026
Bio-Rad Laboratories USD 53.9M 10M Dec/2025
Bruker USD 10.2M 66.1M Mar/2026
Cardinal Health USD 861M 98M Mar/2026
Charles River Laboratories USD 119.9M 44.08M Mar/2026
Cigna USD 2.76B 204M Mar/2026
Concord Medical Services Hldg CNY -144.65M 69.38M Jun/2025
CVS Health USD 4.68B 2.57B Mar/2026
Danaher USD 1.34B 158M Mar/2026
Dentsply International USD 32M 506M Mar/2026
Elevance Health USD -5.81B 6.39B Mar/2026
Humana USD 1.75B 2.56B Mar/2026
Illumina USD 239M 17M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
Intrexon USD -60.84M 26.62M Jun/2024
IQVIA Holdings USD 565M 2.11B Mar/2026
Laboratory Of America USD 410.1M 28.1M Mar/2026
Lakefront Biotherapeutics EUR -63.7M 844.26M Mar/2026
Lonza CHF 673M 243M Jun/2025
McKesson USD 1.84B 181M Mar/2026
Merck EUR 474M 738M Dec/2025
Mettler Toledo International USD 233.93M 118M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Quest Diagnostics USD 399M 13M Mar/2026
Revvity USD 82.77M 63.06M Mar/2026
Thermo Fisher Scientific USD 1.91B 389M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
UnitedHealth USD 9.04B 5.78B Mar/2026
Veradigm USD -45.47M 70.47M Dec/2022
Waters USD 148M 122.52M Mar/2026
West Pharmaceutical Services USD 177.1M 14.6M Mar/2026